Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.46 |
| ▸ | LIPE | Q05469 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747266 | 1.00 | NR1H2 (0.51) | NR1H2DDB1CRBNLIPEGPR119 | |
| SCHEMBL16199623 | 1.00 | NR1H2 (0.51) | NR1H2DDB1CRBNLIPEGPR119 | |
| SCHEMBL15077724 | 0.90 | GPR119 (0.48) | NR1H2GPR119KDM4EMAPTTHRB | |
| SCHEMBL5938533 | 0.90 | GPR119 (0.48) | NR1H2GPR119KDM4EMAPTTHRB | |
| SCHEMBL26963296 | 0.90 | GPR119 (0.48) | NR1H2GPR119KDM4EMAPTTHRB | |
| SCHEMBL25048178 | 0.90 | GPR119 (0.48) | NR1H2GPR119KDM4EMAPTTHRB | |
| SCHEMBL5937898 | 0.90 | GPR119 (0.48) | NR1H2GPR119KDM4EMAPTTHRB | |
| SCHEMBL13727442 | 0.89 | NR1H2 (0.58) | NR1H2DDB1CRBNLIPEGPR119 | |
| SCHEMBL20566526 | 0.89 | NR1H2 (0.58) | NR1H2DDB1CRBNLIPEGPR119 | |
| SCHEMBL22270526 | 0.89 | NR1H2 (0.58) | NR1H2DDB1CRBNLIPEGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287290-A1 | Azabicyclic compounds are central nervous system active agents | DART MICHAEL J | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287290-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHAT, CHRNA6 | NR1H2 570/4885DDB1 1154/4885CRBN 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.